A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-TREATMENT, THREE-PERIOD, CROSSOVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF 61 MG AND 70 MG TAFAMIDIS FREE ACID TABLETS TO COMMERCIAL 61 MG TAFAMIDIS FREE ACID CAPSULE ADMINISTERED UNDER FASTED CONDITIONS IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 26 Jun 2024 Status changed from active, no longer recruiting to completed.
- 29 Mar 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 27 Feb 2024 New trial record